chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After 15 minutes after vaccine injection, patient developed perfuse sweating, light headedness, shaky, nausea, and blood pressure 101/53 (normally 120/80 for him).
Reddened, raised, tender, warm to touch area approx 2" x 3" at Varicella injection site. T. 99.3. C/o slight nausea, seen in our Public Health Office at 10 AM 6-5-09. Recovered cold to site and TYLENOL or MOTRIN as directed. Phone call on 6-8 reports much improved.
Drop of blood pressure several times during the night/morning having to lay down in order not to pass out. Same happened with second dose but that time was 5 min after receiving the vaccine and during the night
Vaccine was expired on 5-17-2019. No signs and symptoms of any adverse reactions. No treatment given.
pt recvd vax & post vax same day pt's leg swelled @ site to 1/2 orange size; 8NOV94 (evening) pt's testicles swelled to walnut size;pt was seen by MD who stated that the pt was having a rxn to vax;tx warm baths;
COULD NOT WALK 4 DAYS; This spontaneous report received from a patient via social media via a company representative concerned a patient of unspecified age, sex, race and ethnicity. The patient's weight, height, and medical history were not reported. The patient previously received covid-19 vaccine ad26. cov2. s (unspecified manufacturer) (Dose number in series 1) (suspension for injection, route of admin, and batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis.  The patient could not walk for 6 days after with first dose of covid-19 vaccine ad26. cov2. s (Dose number in series 1). The patient recovered from could not walk for 6 days. The patient additionally received covid-19 vaccine ad26.cov2.s (unspecified manufacturer) (Dose number in series 2) (suspension for injection, route of admin, and batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patient could not walk 4 days after dose 2 (Dose number in series 2) Reporter stated, "I could not walk x 6 days after 1 and then 4 days after 2 shot, scarey, very scarey" The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of could not walk 4 days was not reported. This report was non-serious. This case, involving the same patient is linked to 20221257284.
Site: Pain at Injection Site-Medium, Additional Details: pt has had arm soreness that started at injection site, but has now travelled to elbow area for four weeks following first dose. Describes it as "bone pain"
Three (3) HPV, lot # (J013324) had bee exposed to the out of range temperature and needed to be returned to clinic. These three vaccines were mistakenly and in administered to three (3) patients. Whoever the staff person was who administered 3 doses of the HPV that should not been used, clicked on the new lot number (J012212) instead of the old lot # (J013324). We have been unable to identify the three patients who received the vaccines exposed to the out of range temp. I have been identify the 12 patients who administered HPV vaccine between the dates of 2/12 - 12/18/`4 under lot number (J012212).
Extremely tired; This spontaneous case was reported by a patient and describes the occurrence of FATIGUE (Extremely tired) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Extremely tired). At the time of the report, FATIGUE (Extremely tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
a swollen round raised bump as in a swollen lymph node on the the left side of the neck area. painful when I touch it. it appeared this morning.
This spontaneous report was received from a physician via a company representative and refers to a 4 year old male patient. The patients' concurrent conditions, medical history and concomitant therapies were not reported. On an unknown date (reported as at 12 months of age), the patient was vaccinated with the first dose of VARIVAX (Merck) (lot #, dose, route of administration and location were not reported) according to Center for Disease Control and Prevention (CDC) recommendation. On an unknown date (reported as an unspecified period of time after receiving first dose of VARIVAX (Merck), the patient developed shingles on an unspecified leg. The physician reported that the patient did resolved after an unspecified amount of time. The physician did not provide causality assessment between the event of shingles on an unspecified leg and therapy with VARIVAX (Merck). Additional information has been requested.
Patient received an additional dose that they were not eligible for. Patient is not immunocompromised.
Pt is a 25 yo male who underwent voluntary COVID-19 testing on 6/26 in preparation for upcoming travel out of the country. Test resulted positive. Patient is s/p complete Pfizer vaccination- first dose 4/15; second dose 5/6. Pt had sinus congestion about 2 weeks ago that he attributed to sinus allergy. Was symptom free 5 days up to COVID-19 testing. Pt underwent second COVID-19 test on 6/27 with another positive result. Advised to quarantine for 10 days, per CDC recommendations.
Patient stated she felt the following symptoms the following day: blurred vision, light headed, injection site pain, inflamed, sensitive to touch, red blotches around injection site, fatigue.
Day 10 (1/14/21) developed quarter sized red patch on left arm at injection sight, that by day 13 (1/17/21) was swollen, large red patch (approximately 8-9 cm in diameter), hot to touch, slightly itchy.
After first shot, started getting phlegm and it kept coming; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRODUCTIVE COUGH (non-serious), outcome "not recovered", described as "After first shot, started getting phlegm and it kept coming".  Additional information: When patient called Pfizer, he was told the he was the only one who experienced phlegm after the first shot, so he just dropped it and did not think much of it.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This case was reported by a nurse via sales rep and described the occurrence of flu syndrome in an unspecified number of adult patients who received SHINGRIX for prophylaxis. On an unknown date, the patients received SHINGRIX at an unknown dose. On an unknown date, unknown after receiving SHINGRIX, the patients experienced flu syndrome, pain, fever and weakness. On an unknown date, the outcome of the flu syndrome, pain, fever and weakness were unknown. It was unknown if the reporter considered the flu syndrome, pain, fever and weakness to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not applicable for this report. The age group was not reported but was captured as adult as per vaccine indication. It was reported that across the 5 practices that the reporter oversees, that they had administered 1540 doses through January. 10 to 15 patients had significant reactions, but only 2 to 3 opted out of receiving the second dose of SHINGRIX. These patients experienced flu syndrome which she described as horrible aching, fever, and stood in the bed. The reporter received these reports from her offices so she could not have any additional details. This case has been linked with US2019AMR044915 and US2019AMR045682 reported by the same reporter.
5/28/12 aching pain to deltoid muscle; 5/29/12 approx 1/4 inch redness at injection point; below point increased aching pain and redness developed approx 1/3"; 5/30/12 AM after rising; a second area of redness developed with possible 3 blisters just below starting point of redness, area approx 1X2". Clear area of skin between both areas of redness. Area is not raised but irregular, not rashy appearing.  Client denies itchiness, headache, fever or flu-like symptoms.
3 weeks after vaccine on 02/18/2021 I was due that to get my 2nd shot and I woke up in bed that morning and I noticed that my neck hurt and I put my hand behind neck and it hurt. I felt a knot on the left base of neck and throughout the day it got more and more tender so I cancelled my vaccine appointment. It went up behind ear and I could feel the chain of lymph nodes that forms behind ear and into my neck. This lasted over two weeks and it hurt pretty bad to move my neck and I thought I had a staph infections and my doctors went through my hair. Altogether I had neck stiffness, tenderness, and a little bit of a headache. I did go to clinic to see my doctor and they had no idea what was wrong. They said it might be a delayed reaction since I have immunoglobin.
sore shoulder; This case was reported by a consumer via call center representative and described the occurrence of shoulder soreness in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced shoulder soreness. On an unknown date, the outcome of the shoulder soreness was recovered/resolved.   It was unknown if the reporter considered the shoulder soreness to be related to Shingrix.  Additional details were provided as follows: The reporter was patient's partner. The age at vaccination was not reported. The age group was not reported but selected as adult as per vaccine indication. The patient experienced sore shoulder after receiving Shingrix. The patient received 2nd dose and experienced same adverse event, refer case US2019AMR184142. Also, this case has been linked to US2019169168 and US2019AMR176794, reported by the same reporter.
Information has been received from a physician concerning his twin teenage daughters who were vaccinated IM with a first 0.5 ml dose of GARDASIL. Subsequently the patients fainted after receiving the vaccination. Both girls also received their second dose with no reaction. Medical attention was not sought. The patients were recovered. No product quality complaint was involved. This is one of the multiple reports from the same source. Additional information has been requested. This is in follow-up to report(s) previously submitted on 1/15/2008.  Information has been received from a physician concerning his 17 year old daughter with no allergies who on 06-OCT-2007 at 11:45 was vaccinated IM with a first 0.5 ml dose of GARDASIL.  The patient fainted after receiving the vaccination.  Medical attention was not sought.  On 06-OCT-2007 the patient recovered.  It was reported that after the second dose was administered the patient had a fainting episode later that night.  No product quality complaint was involved.  It was also reported that the patient and her sibling faint if they receive any injection or lab work.  They also faint if they are in the office for an extended period of time.  It has been going on their entire life since age 5.  If one sister was ill and received treatment or lab work the other sister who was not ill will faint.  Their father is also a fainter.  The patient's twin sister also fainted after receiving a dose of GARDASIL (WAES#0712USA02825).  Additional information is not expected.
Within minutes of pt receiving injection, pt verbalized feeling butterflies in the stomach, lightheadedness and tightening of the throat. Epi-pen and Benadryl 50mg were given 5 minutes after symptoms were reported. Pt was transported via EMS to ED
Client called today to say she had numbness and felt cold to the area where she received the vaccine , the 2nd night after receiving the shot but massaged the area and it went away. Says it didn't last long but thought the vaccine may have caused that and was asking me if was and whether she should no longer receive any vaccines. I asked if she continued with numbness or cold feeling and she stated no. Explained to the VIS statement, asked if she still had hers and she replied no. I told her I would file a VAERS report, also to seek Medical doctor if she had any further questions.
Patient received moderna vaccine on 2/9/21, 3/9/21, 10/28/21, and 5/3/22. Presented to ER on 7/5/22. COVID positive on 6/27/22. present on 7/5/22 because of worsening shortness of breath and cough for a few days. home COVID test + on 6/27/22. CT angio of the chest- Tiny focus of acute pulmonary thromboembolic disease involving a subsegmental branch of the right lower lobe. Significant mucous plugging in the lung bases with mild consolidative changes- atelectasis and/or pneumonia. Lymphadenopathy. Recommend to follow next 2-3 months for resolution. He was also given DuoNeb and Solu-Medrol.   Patient is diagnosed and treat as shortness of breath likely with hypoxia with COVID-19 pneumonia, COPD exacerbation, acute PE with subtherapeutic INR, Pulmonary consulted.  Treated with IV Solu-Medrol, Rocephin, doxycycline, Remdesivir- completed 5 days. Respiratory culture showed Gram-positive cocci in pairs and clusters. TSH 0.15, decrease dose of levothyroxine. Patient condition is improved and not required oxygen at the day of discharge. Based on 6 minutes walk test , patient is not qualified for home oxygen. Patient is moderate- high risk for readmission because of underlying COPD. Discharged on 7/10/22.
Red and swollen 3" x 4" (size), some itching and pain. Clobetasol propionate cream.
Body aches; Arm was sore; Couldn't lift arm; Body feeling hot; Extremeties feeling cold; Couldn't sleep; Chills / shivering really bad; Headache; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of PAIN (Body aches), PAIN IN EXTREMITY (Arm was sore), MOBILITY DECREASED (Couldn't lift arm), FEELING HOT (Body feeling hot) and FEELING COLD (Extremeties feeling cold) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Migraine headache.  On 05-Jan-2021 at 8:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Jan-2021 at 3:00 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HEADACHE (Headache). On 05-Jan-2021 at 8:00 PM, the patient experienced PAIN (Body aches), PAIN IN EXTREMITY (Arm was sore), MOBILITY DECREASED (Couldn't lift arm), FEELING HOT (Body feeling hot), FEELING COLD (Extremeties feeling cold), INSOMNIA (Couldn't sleep) and CHILLS (Chills / shivering really bad). On 06-Jan-2021 at 3:00 AM, INSOMNIA (Couldn't sleep) outcome was unknown. At the time of the report, PAIN (Body aches), PAIN IN EXTREMITY (Arm was sore), MOBILITY DECREASED (Couldn't lift arm), FEELING HOT (Body feeling hot), FEELING COLD (Extremeties feeling cold) and CHILLS (Chills / shivering really bad) outcome was unknown and HEADACHE (Headache) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jan-2021, Body temperature: Low and normal.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  Treatment included ibuprofen.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Five days after the first dose of the vaccine I got a migraine. The migraine was much worse than any I have had before and it lasted for five days. I was unable to get out of my bed and light really bothered my eyes. My vision was blurry. The following week I had feelings of dizziness and nausea. I went to the ER two times because I felt very faint. I was still getting dizziness with heart palpitations and headaches for  two months after the vaccine.  My blood pressure was very low for a month and my surgery for my Gallbladder had to be postponed for two and a half months. My headaches have not been happening as often at this time after twelve weeks. My low blood pressure has improved and I was able to get my surgery. I have not gotten the second dose because I do not want to repeat the experience.  Emergency Room Kaiser, Anaheim
Patient received flu vaccine on 10/5/18 and called today as her arm has not been the same since flu vaccine. She said questioned pharmacist as it seemed too high up in the shoulder maybe an inch below the tip of shoulder but was advised it's the correct place. She Googled the route and site of flu vaccine and how if not given at proper place can cause damage. Advised patient to stop by but she did not left her a message. She did not seek any medical visit.
This spontaneous report was received from a licensed practical nurse referring to a patient of unknown age and gender. There was no concomitant medication. Information about concurrent conditions and medical history was not provided. On 25-APR-2017 at 10:00 am, the last recorded temperature of the vaccines was 4 Celsius degree. On the same day at unspecified time, the ROTATEQ were discovered out of temperature range (refrigerator temperature was 12.7 Celsius degree). The vaccines were not moved to a working refrigerator post the event. It was also reported that the vaccines experienced a temperature excursion during 1 hour 17 minutes. No previous temperature excursion was reported. A data logger issue was involved. On 25-MAY-2017, the patient was vaccinated with improperly stored doses of ROTATEQ (lot number M039067 with expiration date of 18-APR-2018; strength and dose were unknown; location was also reported as "2", dose number was also reported as "0"; Vaccines for Children Program (VFC) stock) orally for prophylaxis. The nurse stated that they would monitor every 30 minutes to insure temperature with range. It was confirmed the vaccines were OK to use. There was no adverse event reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1704USA014144.
Immunized 3/3 returned on 3/5 with warm diffuse swelling of (R) arm- no fever, no itch, mild pain.
Fever 101, Redness to Area, Stiffness of right arm, pain in shoulder and neck.
Client received PNEUMOVAX 23 on 08/22/16 at 10:24 am. At 3:27 pm client reported to the emergency room complaining of pain, swelling, and redness at injection site; and she "had a hard time breathing for a little bit". Client was given Prednisone 40 mg 1 tab PO, PEPCID 20mg 1 tab PO and BENADRYL 25mg 1 tab PO. Client was discharged home. Per client swelling resolved on its own in 1-2 days.
He had not been experiencing any issues or symptoms of his chronic illnesses, but within 1 day had CHF symptoms and died; This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation.  Medical history included chronic kidney disease, Congestive heart failure (CHF), hypertension, diabetes mellitus. The concomitant drugs included other unspecified medications in two weeks. There were no covid prior vaccination, and no covid tested post vaccination. The patient had not been experiencing any issues or symptoms of his chronic illnesses, but within 1 day had CHF symptoms and died in Mar2021, which resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event), died. The patient was hospitalized for 1 days. Treatment was received. The patient died in Mar2021.  The event was listed as complication of Covid 19 vaccination. It was not reported if an autopsy was performed.   Information on the lot/batch number has been requested.; Reported Cause(s) of Death: He had not been experiencing any issues or symptoms of his chronic illnesses, but within 1 day had CHF symptoms and died
Information has been received from a consumer concerning his daughter, a female with a history of drug hypersensitivity who in December 2007, was vaccinated with the first dose of Gardasil.  In February of 2008 the patient was vaccinated with the second dose of Gardasil.  Concomitant therapy included IMITREX and hepatitis A virus vaccine (unspecified).  Per the reporter, "four hours after the patient received the vaccines, she became paralyzed from the neck down, which lasted about 9 hours.  The patient also had numbness and tingling all over her body.  She was rushed to the emergency room and was released after the 9 hours.  The experience has improved but the patient still occasionally experiences numbness and tingling in her arms.  Also, sometimes when the patient goes to pick something up, she cannot because her arms and hands just won't move."  No lot number was provided and no further information was provided.  The reporter did state that he will call back with the lot number.  Paralysis was considered to be an other important medical event.  Additional information has been requested. 03/07/08 Vax record confirms Gardasil dose #1, Hep A#1. 03/19/2008 MR received for ER visit 2/6/2008 with Final Impression Generalized weakness-resolved. Pt presented to ER with c/o difficulty moving extremities x several hours. Pt states both arms and legs are weak with tingling. SOB now resolved.  Pt had migraine h/a earlier in the day, txd with Imitrex.  PE WNL. 4/4/2008 MR received from PCP for OV 2/7/2008 re: above ER visit.  Pt had 2 similar but milder episode of weakness on 2/7/08. PE WNL. DX:  Weakness; iron def anemia. To return if sx recur.  Pt not seen in office since 2/7/08 per office RN.
heart palpitations (approx 5 weeks duration), extreme fatigue (approx 1 week duration), somnolence (approx 1 week duration),
high fever; Nausea; Headache; Dizziness; Weakness; This is a spontaneous report from a contactable consumer (patient husband). A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for COVID-19 immunisation. Medical history included previously they both had covid last year (2020). The patient's concomitant medications were not reported. The patient took the first dose of the covid vaccine on Saturday. The patient had reactions of high fever, some nausea, and headaches and then that passed. The patient had been experiencing dizziness and weakness. The reporter was asking what she can do about it and how long it would last for her. Outcome of events fever, nausea, headaches was recovered; dizziness, weakness was unknown.  Follow-up attempts completed. No further information expected.
After first dose blood sugar elevated then after second dose blood sugar stayed elevated and experienced an increase in Depressed mood. "I had a melt down" 2 days after the second shot. She received energy work and symptoms went away and she returned to base line.